<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364505">
  <stage>Registered</stage>
  <submitdate>26/06/2013</submitdate>
  <approvaldate>4/07/2013</approvaldate>
  <actrnumber>ACTRN12613000749707</actrnumber>
  <trial_identification>
    <studytitle>Factors controlling calciprotein particle (CPP) formation in peritoneal dialysis (PD) fluid </studytitle>
    <scientifictitle>Assessing the peritoneal dialysis effluent for the presence of calciprotein particles in patients undergoing peritoneal dialysis </scientifictitle>
    <utrn />
    <trialacronym>PDF Study</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>End stage kidney disease </healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Assessing the peritoneal dialysis effluent for the presence of calciprotein particles. Once a week for 8 weeks, in no particular order, participants will administer a specified PD fluid bag (listed below) and return that bag of effluent for analysis. The PD bags are:
1. Dianeal 1.5% PD4 
2. Dianeal 4.25%  PD4 
3. Physioneal 1.36% PD4 
4. Physioneal 3.86 % PD4 
5. Extraneal 7.5%  
6. Nutrineal 1.1%  
7. Dianeal 1.5% PD2 
8. Dianeal 1.5% PD1 
</interventions>
    <comparator>Nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>CPP levels will be estimated by assessing the apparent reduction in total fetuin-A concentration (measured by specific ELISA) after high-speed centrifugation as previously described in Smith ER et al 2013 Nephrology 18(3):215-21.</outcome>
      <timepoint>Once a week after each exchange for 8 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Fluid pH will be measured by potentiometry using a pH electrode. </outcome>
      <timepoint>Once a week after each exchange for 8 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Peritoneal dialysis patients 
A peritoneal equilibration test (PET) within the last 6 months
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Unable to comply with the protocol
Allergy or problem with one of the PD fluid solutions proposed
Peritonitis within the last 6 weeks
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods>Statistical analysis based upon preliminary data where the mean CPP% in PD fluid is 21 with standard deviation of 5. A sample size of 14 patients should detect a significant 5% difference (p&lt;0.05) in mean CPP level with a 80% power.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>22/07/2013</anticipatedstartdate>
    <actualstartdate>14/10/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate>1/09/2015</actualenddate>
    <samplesize>15</samplesize>
    <actualsamplesize>13</actualsamplesize>
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Eastern Health Integrated Renal Service</primarysponsorname>
    <primarysponsoraddress>Level 2, 5 Arnold Street
Box Hill, Victoria, 3128</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Baxter Healthcare Corporation </fundingname>
      <fundingaddress>One Baxter Parkway 
Deerfield, IL 60015</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>The Royal Melbourne Hospital Kidney Care Services</sponsorname>
      <sponsoraddress>Grattan St Parkville VIC 3050
</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>There is a need to better understand the mechanisms involved in peritoneal membrane deterioration in patients undergoing peritoneal dialysis. We have found that a recently discovered particle (calciprotein particle, CPP) is present at high levels in drained out peritoneal dialysis fluid (PDF). Experimental work suggests that CPP may promote inflammation and calcification in certain situations. This is a pilot study to ascertain whether differences in PDF composition, in particular with respect to fluid glucose and calcium concentration, effect the formation and levels of CPP present in drained PDF. We hypothesise that PDF containing higher glucose and calcium concentrations would be associated with greater intra-peritoneal CPP accumulation, which may predispose to peritoneal inflammation, calcification and ultimately, technique failure. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Eastern Health Research and Ethics Committee</ethicname>
      <ethicaddress>5 Arnold Street
Box Hill, Victoria, 3128</ethicaddress>
      <ethicapprovaldate>21/03/2013</ethicapprovaldate>
      <hrec>LR73/1213</hrec>
      <ethicsubmitdate>12/03/2013</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Lawrence McMahon</name>
      <address>Eastern Health Integrated Renal Service
Level 2, 5 Arnold Street
Box Hill, Victoria, 3128</address>
      <phone>+61 3 9091 8872</phone>
      <fax />
      <email>lawrence.mcmahon@easternhealth.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Steve Holt</name>
      <address>The Royal Melbourne Hospital Kidney Care Services Hospital Grattan St 
Parkville, Victoria, 3050
</address>
      <phone>+61 3 9342 7058 </phone>
      <fax />
      <email>steve.holt@mh.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Ed Smith</name>
      <address>Eastern Health Integrated Renal Service
Level 2, 5 Arnold Street
Box Hill, Victoria, 3128</address>
      <phone>+61 3 9091 8872</phone>
      <fax />
      <email>ed.smith@monash.edu</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Annette Kent</name>
      <address>Eastern Health Integrated Renal Service
Level 2, 5 Arnold Street
Box Hill, Victoria, 3128</address>
      <phone>+61 3 9091 8871</phone>
      <fax />
      <email>annette.kent@easternhealth.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>